Stem cell islet replacement in type 1 diabetes: From "shelf" to "self"

Area of Science:

• Regenerative Medicine
• Endocrinology
• Stem Cell Biology

Background:

• Type 1 diabetes is an autoimmune disease characterized by the destruction of insulin-producing beta cells.
• Current treatments involve lifelong insulin replacement therapy, which has limitations.
• Cellular therapies aim to restore endogenous insulin production.

Purpose of the Study:

• To report the functional cure of a patient with type 1 diabetes.
• To evaluate the efficacy of transplanting autologous induced pluripotent stem cell (iPSC)-derived islets.
• To assess the safety and viability of islet transplantation in a non-pancreatic site.

Main Methods:

• Generation of induced pluripotent stem cells (iPSCs) from the patient's somatic cells.
• Differentiation of iPSCs into insulin-producing islet cells.
• Transplantation of these autologous iPSC-derived islets into the rectus abdominis muscle.
• Monitoring of glycemic control and insulin independence post-transplantation.

Main Results:

• The patient achieved functional cure of type 1 diabetes.
• Sustained insulin independence was observed post-transplantation.
• The transplanted islets demonstrated appropriate glucose responsiveness and insulin secretion.
• No major adverse events related to the transplantation were reported.

Conclusions:

• Autologous iPSC-derived islet transplantation is a viable strategy for achieving functional cure in type 1 diabetes.
• This approach offers a potential alternative to pancreas or whole-islet transplantation.
• Further research is warranted to validate these findings in larger cohorts.